ACTG Launches Landmark Study Evaluating Treatments for Depressive Disorders with or without Mild Neurocognitive Disorder among People Living with HIV
CHAPEL HILL, N.C., April 24, 2026 (GLOBE NEWSWIRE) — ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of study A5402, an important new study that researchers hope will expand understanding of how to best treat depressive disorders and mild neurocognitive disorder (MND) among people living with […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.